一、个人简历

周文，上海交通大学药物化学博士，研究员，博士生导师，现任动物抗感染药物和微生物耐药团队首席，入选上海市东方英才拔尖、广州市人才、上海交通大学SMC-晨星计划、广州中医药大学青年杏林学者，曾担任广东省“珠江学者”药物化学岗位学科带头人，现任Veterinary Sciences、Frontiers in Pharmacology编委、《天然产物研究与开发》青年编委、APSB, J. Med. Chem., Eur. J. Med. Chem.,等药化顶级期刊通讯评审专家等。兼任山东大学博导、河南农业大学博导、上海应用技术大学硕导、中国农业科学院学术委员会委员、中国畜牧兽医学会兽医药理毒理学分会常务理事、上海市畜牧兽医学会动物药品分会理事长、上海饲料兽药行业协会理事、上海市宠物食品药品专业委员会副主任委员等。

长期从事类药分子设计合成、成药性评价以及药物创制及其关键共性技术研究，主持完成糖类药物候选化合物HSCD-54和蒽醌类NR-20成药性研究、以及北卡罗来纳州Glycan Therapeutics, LLC用于商业化的硫酸肝素类糖芯片构建研究，作为主要完成人参与紫草素肟DMSK-20临床前药物评价。主持参与国家自然科学面上基金 (3项)、国家自然科学基金联合基金、国家自然科学基金重点项目、国家重大新药创制、上海市生物医药支撑、NIH、FDA等项目28项，培养（含联合培养）博士生7名、硕士生14名、博士后2名。在《Nature Product Reports》《Cell Report Medicine》 《Journal of Medicinal Chemistry》《European Journal of Medicinal Chemistry》《Chemical Communication》《Cancer Research》等国内外发论文120篇，其中SCI论文108篇，出版专（译）著7部，获授权专利14项。

二、 联系方式

办公电话：021-34293460

邮      箱：wzhou60@shvri.ac.cn 或zhouwen60@126.com

三、代表论著

1. Lv S.#, Ma R.M.#, Tang Q.#, Wang X.Y., Wang C.M., Zhang K.Y. Li H.K., Ye W.C.* and Zhou W.*, Discovery of 3,4-dihydropyrimidine derivatives as novel Anti-PEDV agents targeting viral internalization through a unique calcium homeostasis disruption mechanism[J], Eur. J. Med. Chem., 2025，291, 117637, doi.org/10.1016/j.ejmech.2025.117637.

2.Yang X.P., Jiao Z.R., Fan C.C., Ye W.C., Sai Lv, Wang X.Y., Wang C.M., Zhang K.Y., Ke X.S.* and  Zhou W*,Macrocyclic Compounds: unveiling their distinctive antiviral advantages in medicinal research[J], J. Med. Chem., 2025, 68 (20),doi: 10.1021/ acs. jmedchem.5c02430.

3. Tang Q.#, Zhang H.Y#, Jiao Z.R., Bai H., Han X.G., Wang X.Y., Zhang K.Y., Wang C.M.* and Zhou W.*,  

4. Qiu F.M.#, Fan C.C#, Tang Q., Chandarajoti K., Wang X.Y., Zhang K.Y., Ye W.C., Wang C.M.* and Zhou W.*,Traditional Chinese Medicine: Dual Antibacterial Actions via Host Defense Balance and Bacterial Inhibition[J], Phytother. Res, 2026, https://doi.org/10.1002/ptr.70235

5. Wang X.Y., Wang C.M., Zhang K.Y., Ge Y.W.* and Zhou W*. Discovery of xanthone‐based nitric oxide donors targeting biofilm clearance[J]. Arch. Pharm. 2025, https://doi.org/10.1002/ ardp.202400793.

6. Ye W.C. #, Tang Q.#, Zhou T., Zhou C., Fan C., Wang X.Y., Wang C.M., Zhang K.Y., Liao G.C.* and Zhou W*.  Design, synthesis and biological evaluation of the positional isomers of the galactose conjugates able to target hepatocellular carcinoma cells via ASGPR-mediated cellular uptake and cytotoxicity[J]. Eur. J. Med. Chem., 2024, 264, 115988.

7. Zhou T, Hao J.K., Tang Q., Chandarajoti. K., Ye W.C., Fan C., Wang X.Y., Wang C.M., Zhang K.Y., Ge Y.W. * and Zhou W*. Antimicrobial activity and structure-activity relationships of molecules containing mono- or di- or oligosaccharides: An update [J]. Bioorganic Chemistry, 2024, https://doi.org/10.1016/ j.bioorg.2024.107406.

8. Ge R.L., Zhou H.Y., Tang Q., Chandarajoti. K., Bai H. Wang X.Y., Zhang K.Y., Han X.G., Wang C.M.* and Zhou W*. A novel a-mangostin derivative synergistic to antibiotics against MRSA with unique mechanisms[J]. Microbiology Spectrum, 2024. https://doi.org/10.1128/spectrum.01631-24.

9. Lu Y. #, Guan T. #, Wang S.B. #, Zhou C., Wang M.Z., Wang X.Y., Zhang K.Y., Han X.G., Lin J.C., Tang Q., Wang C.M.* and Zhou W.* Novel xanthone antibacterials: Semi-synthesis, biological evaluation, and the action mechanisms [J]. Bioorg. Med. Chem., 2023, https://doi.org/10.1016/ j.bmc.2023.117232.

10. Long Q., Zhou W., Zhou H., Tang Y., Chen W.*, Liu Q.* and Bian X.* Polyamine-containing natural products: structure, bioactivity, and biosynthesis[J]. Nat. Prod. Rep., 2024, DOI: 10.1039/d2np00087c.

11. Chen W.M. #, Zhou C. #, Chen J.S., Wang M.Z., Zhou F., Wang C.M. *, Zhang X.* and Zhou W. *, Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives[J]. Bioorg.Chem., 2022. doi.org/10.1016/j.bioorg. 2021.105515.

12. Zhou C.#, Ye W. C.#, Cao Y.J.#, Wang M.Z., Qi D.X., Liao G.C., Li H.K., Huang W.P., Chen W.M.* Wang X.Y.* and Zhou W,* A gulose moiety contributes to the belomycin (BLM) disaccharide selective targeting to lung cancer cells[J]. Eur. J. Med. Chem. 2021,  doi.org/10.1016/j.ejmech.2021.113866，226:113866.

13. Wang M.Z. #, Chen W.M.#, Chen J.S., Yuan, S.S., Hu J.J., Han B.X., Huang Y.H.* and Zhou W.* Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies[J]. Eur. J. Med. Chem. 2021, doi.org/10.1016/j.ejmech.1021.113487.

14. He X.G., Li M.L., Ye W.C. and Zhou W.* Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC) [J]. Bioorg. Chem. 2021, 107, doi.org/ 10.1016/j. bioorg.2020.104574.

15. Chen P.#, Wang S. B.#, Cao C. Y.#, Ye W. C., Wang M.Z., Zhou C., Chen W.M., Zhang X., Zhang K.Y.* and Zhou W.,*α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship, Bioorg. Chem., 2021, doi.org/10.1016 /j.bioorg.2021.105295.

四、专利标准

1) 周文，王春梅，鲁研等，氧杂蒽酮酯类与糖类衍生物及其制备与抗菌用途，2024，中国发明专利，ZL202210872955.0.

2) 周文，酶化学合成结构明确的硫酸肝素寡糖的方法, 2021, 中国发明专利，ZL201810539159.09.

3) 周文，李茂林，袁思思，一种3-O-氨基甲酰甘露糖供体衍生物、博来霉素二糖及其前体的制备方法, 2021，中国发明专利，ZL2018105770218.

4) 周文，李茂林，袁思思，一种2-羟基古洛糖受体衍生物、博来霉素二糖及其前体的制备方法，2021，中国发明专利，ZL2018105770932.

5) 周文, 硫酸肝素与FK506共轭物酶化学合成以及应用，2020，中国发明专利，ZL201810 444478.1.

6) 周文，一种取代苄基或取代苯基b-D-己糖醛酸糖苷的制备方法，2020，中国发明专利，ZL201810503213.4.